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ABSTRACT
Introduction: Asthma affects 30 million people
in Western Europe, leading to substantial
burden on healthcare systems and economies.
REcognise Asthma and LInk to Symptoms and
Experience (REALISETM) was a large European
survey across 11 countries assessing patient
attitudes and behaviors towards their asthma.
The present study utilizes REALISETM data to
understand resource use and absenteeism in
asthma.
Methods: Data were collected on absenteeism
and healthcare resource use from 8000 asthma
patients (aged 18–50 years) across the 11 countries.
All data were patient reported. Odds ratios
(ORs) were calculated against the country with
the lowest proportion of respondents for
hospitalization (as a proxy for lowest resource use).
Results: Patient characteristics were broadly
similar across countries. However, self-reported
asthma control status varied. More than 50% of
respondents in most countries considered
primary healthcare professionals (HCPs), i.e.,
general practitioners and nurses, the main HCP
they see about their asthma. However, in some
countries, specialists or nurses were considered
the main HCP. Hospitalization was lowest
amongst patients in the Netherlands. Resource
use and productivity loss varied widely across
the countries; ORs for hospitalization ranged
from 1 in Sweden to 4 in Norway and for
productivity loss from 0.6 in Sweden to 2.6 in
Italy, compared with the Netherlands.
Conclusion: This study quantified utilization of
healthcare resources in asthma (number of
visits of HCPs, hospitalization, and accident
Electronic supplementary material The online
version of this article (doi:10.1007/s12325-015-0204-6)
contains supplementary material, which is available to
authorized users.
M. Fletcher
CEO Office, Education for Health, Warwick, UK
A. Jha  W. Dunlop (&)
Market Access, Mundipharma International,
Cambridge, UK
e-mail: will.dunlop@mundipharma.co.uk
L. Heron  V. Wolfram
Value, Insight and Communication, Adelphi Values,
Bollington, UK
T. Van der Molen
University of Groningen, University Medical Centre
Groningen, Groningen, The Netherlands
D. Price
Division of Applied Health Sciences, University of
Aberdeen, Aberdeen, UK
Adv Ther (2015) 32:370–380
DOI 10.1007/s12325-015-0204-6
and emergency visits) as well as absenteeism
and showed that differences exist across
countries. The differences in primary care and
specialist use suggest a possible difference in
healthcare delivery across countries.
Funding: Mundipharma International Limited,
Cambridge, UK.
Keywords: Asthma; Patient-reported;
Productivity; Resource use
INTRODUCTION
Asthma is a common chronic disease of the
respiratory system affecting approximately 30
million people in Western Europe [1] and is a
serious public health issue. Both direct and
indirect per patient costs associated with
asthma are high [2, 3] and total asthma care
costs are estimated at £18 billion per year in
Europe [4]. Resource use due to asthma varies
across several European countries but is
generally high [2, 4, 5]. For example, in France
and Spain, estimated per patient costs for a
3-month period were up to €537.9 and €556.8,
respectively [2]. Furthermore, absence from
work or education due to asthma is also
common [2, 5, 6]. In France and Spain,
estimated indirect costs accounted for up to
63% and 59% of total costs, respectively [2].
Patients with asthma may achieve various
levels of control of their asthma, depending on
several factors, which may include severity,
exposure to triggers, treatments and patient
adherence to treatment. The Global Initiative
for Asthma (GINA) has developed
recommendations to help establish local
guidelines that inform and support health
professionals’ assessment and management of
asthma patients. The GINA report defines and
categorizes asthma control levels as ‘well
controlled’, ‘partly controlled’, and
‘uncontrolled’ based on daytime symptoms,
normal activities affected by symptoms,
nighttime awakenings, and reliever inhaler use
[7]. The recommendations are that
management and treatment should be driven
by these control levels [7]. However, despite
GINA recommendations and existing local
guidelines, there are no standard management
algorithms or practices for asthma patients
across Europe.
The REcognise Asthma and LInk to
Symptoms and Experience (REALISETM) survey
investigated asthma control and evaluated
patient perception of control and attitudes to
asthma in a large European Union-based
population. The data were collected from adult
patients with asthma requiring treatment across
11 European countries and included 8000
individuals [8]. In addition, the survey also
collected data on patient utilization of
healthcare resources and time off work,
providing a unique opportunity to assess the
resource burden and lost productivity
associated with asthma.
Using results from the REALISETM study, the
objective of this research was to understand the
burden of asthma by reviewing resource use
[number of visits of healthcare professionals
(HCPs), hospitalization, and accident and
emergency (A&E) visits] and lost productivity
(absence from work or education) in 11
European countries.
METHODS
Survey
The REALISETM survey is a quantitative online
survey conducted in 11 European countries
(Austria, Belgium, Finland, France, Germany,
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Italy, the Netherlands, Norway, Spain, Sweden,
and the UK) between July and October 2012. Full
details of the survey design are published
elsewhere [8]. The survey population was drawn
from validated online consumer panels that met
International Organization for Standardization
20252 quality standards; multiple panels were
used to reduce potential bias. Respondents who
had participated in market research surveys
within the previous 3 months were excluded.
Eligible respondents were aged 18–50 years, had
clinically diagnosed asthma, at least two
prescriptions for asthma in the previous 2 years,
and previously used social media. The target
survey population was 8000; additional
respondents were not recruited once this
number was achieved. Each respondent received
an incentive for participating in the research.
The survey collected data on asthma control,
asthma management, resource use (e.g.,
number of hospitalizations) and work
productivity (absence from work/education).
All data, including confirmation of asthma
diagnosis, were patient-reported. Respondents
were asked whether they had an asthma
diagnosis from a doctor and whether they had
two or more prescriptions for their asthma in
the past 2 years. Asthma control was assessed
using the four GINA criteria: daytime
symptoms, nighttime symptoms, limitations
of daily activities, and need of reliever inhaler.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. Data were managed in
accordance with the Data Protection Act (UK,
1998).
Data Analysis
Responses relating to demographics and
smoking status, asthma severity, resource use,
and absenteeism are reported and summary
tables produced. Continuous variables are
presented as means. Categorical variables are
presented as counts and proportions. When
calculating means in situations where the
response options were categorical, counts of
C5 or C10 (as an answer option) were assumed
to be 5 or 10, respectively (i.e., the lowest value
in the range). Respondents were asked which
HCP they visited most frequently about their
asthma; respondents who answered ‘‘I do not
see a healthcare professional about my asthma’’
were excluded from answering the next
question of how many times in the past year
the respondent had visited the HCP. Answers of
‘‘less than once a year’’ were assumed to be zero
during the previous 12 months.
Resource use was measured by quantifying
how many times a patient reported seeing their
main HCP for their asthma or being treated in an
A&E department in the previous year. In
addition, the number of hospitalizations with
an overnight stay relating to asthma during the
previous year was reported by each respondent.
Number of days of hospitalization was not
reported. Productivity loss was measured in
days off work or education. To calculate relative
resource use and productivity, odds ratios (ORs)
were calculated against the country with the
lowest proportion of respondents for
hospitalization (as a proxy for lowest resource
use). The OR was calculated by dividing the
country ratio (respondents using resource versus
respondents not using resource) by the reference
country ratio (respondents using resource versus
respondents not using resource) across all
countries.
Productivity and resource use by type of HCP
were further analyzed in cross-tabulations.
Analyses were performed using SPSS version
9.0 (SPSS, Inc., Chicago, IL, USA). As there were
no a priori hypotheses, and to control for type I
family-wise error rate (the probability of at least
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1 incorrect rejection of null), effect sizing was
determined using the false discovery rate
method [9]. The proportion of errors among
those tests whose null hypotheses were rejected
was set at 5% and P values were calculated to
determine statistical significance.
RESULTS
Survey Population and Respondent
Characteristics
The analysis included 8000 respondents aged
18–50 years. France, Spain, Italy, Germany, and
the UK reported the largest samples (N C 1000).
Table 1 shows the respondents’ mean age, sex,
and smoking status as well as self-reported
clinical factors (e.g., controlled GINA status,
asthma exacerbation), and ownership and use
of preventer inhaler by country.
The mean age range was 32–37 years and
between 17% and 26% of respondents were
current smokers: patient demographics were
broadly similar across countries and statistically
significant differences were reported in only a few
instances, e.g., respondents in the Netherlands
were older than in other countries. The
proportion of female respondents was higher in
the Netherlands and the UK compared to other
countries in the study. The most commonly
reported comorbidities were depression and high
blood pressure/hypertension, reported by up to
30% of respondents in some countries. Chronic
obstructive pulmonary disease, cancer, heart
disease, diabetes, and rheumatoid arthritis were
reported by less than 10% of respondents in most
countries.
On average, 20% of respondents in this study
had a controlled GINA status (self-reported),
this ranged from 15% in Germany to 28% in
Austria. Self-reported asthma exacerbation,
indicated by the requirement of at least one
course of steroid tablets in the previous
12 months, was highest among respondents in
Italy compared with respondents in other
countries. In each country in the study, at
least one in four respondents possessed a
preventer inhaler. Of these respondents, daily
use of preventer inhaler was highest in the
Netherlands (61%) and Germany (61%) and
lowest in Spain (25%). Additionally, between
19% (UK) and 32% (Spain) of respondents
owned a combination inhaler (i.e.,
combination inhaled corticosteroid/long-
acting beta agonist) and between 7% (UK) and
30% (Belgium) of respondents took oral
treatment to help manage their asthma.
HCPs That Respondents Would Consult
as the Main HCP for Their Asthma
In all countries, except for Austria, most
respondents considered general practitioners
(GPs) to be the main HCP they would consult
about their asthma (Fig. 1). The UK was unique
among the respondent sample, in that over
25% of respondents considered a nurse to be
their main asthma HCP and fewer respondents
(4%) would consider seeing a specialist. In
contrast, at least 10% of respondents in all
other countries considered a specialist as the
main HCP they would consult about their
asthma; this was highest in Austria (50%)
followed by Germany (42%), Spain (37%),
and Italy (35%).
Self-Reported Resource Use and Absence
From Work or Education Amongst
the Respondents in Different Countries
Table 2 reports resource use and absenteeism by
country, relative to the Netherlands (that had
Adv Ther (2015) 32:370–380 373
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the lowest resource use as measured by proxy
indicator of hospitalization).
Proportionally fewer respondents in Sweden
and Finland reported visiting their main HCP in
the previous 12 months compared with those in
the Netherlands, while visits to the main HCP
were up to 3.7 times (Germany) more likely in
other countries. Hospitalization was up to four
times more likely in Norway and A&E visits
were up four times more likely in Norway,
Finland, Germany, and Spain compared with
the Netherlands. Several countries including
Sweden and the UK reported less absenteeism
compared with the Netherlands; only Germany,
Spain, Italy, and Norway reported more.
Resource Use and Absence From Work
or Education by HCP
Overall, 17% of respondents who considered a
specialist as their main asthma HCP reported
being hospitalized at least once in the previous
12 months, compared with 10% of respondents
who considered a GP and 10% who considered a
nurse their main asthma HCP (P B 0.05; Fig. 2).
Respondents who considered a specialist their
main asthma HCP (rather than a GP or a nurse)
were more likely to be treated at A&E at least
once in the previous 12 months (32% specialist,
21% GP, 17% nurse, P B 0.05). Additionally,
these respondents also take C1 day off work or
education (38% specialist, 30% GP, 22% nurse,
P B 0.05; Fig. 2).
DISCUSSION
This study used the results of the REALISETM
study to quantify some key healthcare resource
use components (number of visits of HCPs,
hospitalization, and A&E visits) across 11
European countries and showed that
utilization varied widely. Primary care plays a
pivotal part in the management of asthma in all
countries with at least three in five respondents
considering a GP or a nurse their main asthma
HCP. However, the use of acute services as
indicated by hospitalization or A&E events was
up to four times higher across other countries in
Europe compared to the Netherlands. These
results indicate that there might be a higher
burden on secondary healthcare in these
countries, or that primary care needs further
investment and development to avoid the need
for patients to go to A&E.
The heterogeneity of HCPs consulted by
patients reported in the REALISETM study
could be due to country-specific asthma
policies or overall differences in healthcare
system structures. In the UK, Sweden, and
Finland for example, asthma nurses are an
integral part of the disease management [10–
12], whereas for example in Germany, asthma
nurses do not form part of the management
Fig. 1 Main healthcare professional respondents consulted
about their asthma, by country. Patients were asked:
‘‘Which healthcare professional would you consider to be
the main person who you see about your asthma?’’ Base:
N = 8000, numbers shown are percentages. AUT Austria,
BEL Belgium, FIN Finland, FRA France, DEU Germany,
GP general practitioner, HCP healthcare professional, ITA
Italy, NLD The Netherlands, NOR Norway, ESP Spain,
SWE Sweden, UK United Kingdom
Adv Ther (2015) 32:370–380 375
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plan [13]. If there is no negative impact on
patients’ asthma control, consulting GPs or
nurses more frequently than specialists could
indicate overall lower costs to healthcare
systems. However, whether such a ‘gatekeeper’
approach is more appropriate for health systems
compared to having the direct access to
specialists is unclear and is the subject of
much debate in the literature [14].
In addition, in Germany many patients are
treated by specialists as German treatment
guidelines stipulate that patients should be
treated by specialists in cases where: asthma is
uncontrolled, long-term treatment with oral
corticosteroids is necessary, patient underwent
previous emergency treatment, comorbidities
exist, suspicion of work-related asthma exists, or
treatment with a specific regimen is indicated
[13]. In Germany, 42% of respondents
considered a specialist their main HCP they
would consult about their asthma. This further
underpins our findings supporting the validity
of our sample frame.
The REALISETM survey was not specifically
designed to assess healthcare burden in the
different countries. However, numbers of
hospitalizations per year were comparable to
the European National Health and Wellness
Survey which had a similar study design
(countries included were France, Germany,
Italy, Spain, and the UK; study design
included self-administered, web-based
questionnaires for asthma patients
aged C18 years who were identified through an
internet-based consumer panel with a sampling
frame that reflected the quotas based on sex and
age demographic distribution of each country)
[5]. In the REALISETM study, number of
hospitalizations per patient annually ranged
from 0.12 in the Netherlands to 0.85 in
Norway compared with a mean of 0.14–0.31
for ‘‘at least well controlled’’ and ‘‘not well
controlled’’ patients across the five countries in
the European National Health and Wellness
Survey [5]. However, proportions of
respondents who reported incidences of A&E
visits and hospitalizations due to asthma in the
REALISETM study were larger than in cost-of-
illness studies conducted in Italy, France, and
Spain [2, 15]. However, the latter study only
included asthma patients treated by GPs [2],
while the Italian study was conducted prior to
2000, therefore comparability between studies
is limited [15].
Proportions of respondents reporting
hospitalization, A&E visits and absence from
work varied across the countries. Similar to
previous reports [16–18] patient-reported
asthma control was low, but resource use and
work absence appeared to be higher in those
countries with low control. This could be due to
differences in asthma control levels: in
Germany, resource use was high but the
proportion of respondents reporting controlled
asthma status was low relative to other
countries.
In addition, overall resource use was higher
for respondents who considered a specialist
their main asthma HCP. It is likely that these
respondents have more severe asthma than
Fig. 2 Proportions of respondents that reported being
treated in A&E, hospitalized or taking time off work or
education during the previous 12 months, categorized by
patient feedback on their main healthcare professional.
A&E accident and emergency, GP general practitioner
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respondents who consult a GP or nurse.
However, due to the study design and analysis
plan, we were unable to adjust for any possible
contributing factors such as the level of asthma
control or severity in this analysis and
recommend that future studies incorporate
stratified analyses or regression techniques in
order to address possible confounding. This
would allow the research to identify the
drivers for higher resource use which could be
the level of asthma control as has been
previously suggested [2, 15]. Patient
demographics, such as age and gender
distribution were similar across most countries
and therefore adjustments were not
incorporated in the between country analyses.
The REALISETM study represents one of the
largest surveys of asthma patients thus far.
However, there are a number of limitations to
be considered. Respondents were not
randomized and only patients aged
18–50 years who used social media
participated in the study; therefore, this
sample might not fully represent the wider
patient population. In addition, the survey was
conducted online in a sample population that
uses social media and as such may be biased
towards this sample of patients. However, there
is no evidence to suggest that these groups of
people are more or less likely to respond and
have any different asthma status or control.
Respondents’ data were based on self-reported
answers without clinical verification, therefore
inaccurate response or recall bias cannot be
excluded. In addition, respondents only
reported how often they visited their main
HCP; however, visits to HCPs not considered
their main HCP were not recorded. The large
sample should account for country
heterogeneity limiting over-representation of
specific patient-types. The respondent
characteristics, proportion of smokers, and
proportion of females, broadly matched that
in previous European studies; only the mean
age was lower which might be due to the age
range set by the inclusion criteria and the
restriction to patients that use social media [2,
3, 6, 18]. The REALISETM study did not capture
the purpose of visits to a GP, nurse, or specialist
therefore routine and review visits as well as
urgent visits might be included.
CONCLUSIONS
The present analysis of the REALISETM data
suggests differences in asthma control status,
HCP, and resource use across 11 European
countries. More research will be required to
validate these results in order to enable
comparison between the health care systems
in the different countries.
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